PL391627A1 - Przeciwnowotworowe białko fuzyjne - Google Patents

Przeciwnowotworowe białko fuzyjne

Info

Publication number
PL391627A1
PL391627A1 PL391627A PL39162710A PL391627A1 PL 391627 A1 PL391627 A1 PL 391627A1 PL 391627 A PL391627 A PL 391627A PL 39162710 A PL39162710 A PL 39162710A PL 391627 A1 PL391627 A1 PL 391627A1
Authority
PL
Poland
Prior art keywords
fusion protein
anticancer fusion
anticancer
protein
fusion
Prior art date
Application number
PL391627A
Other languages
English (en)
Inventor
Jerzy Szczepan Pieczykolan
Krzysztof Kazimierz Lemke
Sebastian Pawlak
Bartłomiej Żerek
Original Assignee
Adamed Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Spółka Z Ograniczoną Odpowiedzialnością filed Critical Adamed Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL391627A priority Critical patent/PL391627A1/pl
Priority to PCT/EP2011/060666 priority patent/WO2011161260A1/en
Priority to UAA201300877A priority patent/UA111722C2/uk
Priority to PT11727457T priority patent/PT2585480E/pt
Priority to CA2800841A priority patent/CA2800841C/en
Priority to MX2012015246A priority patent/MX2012015246A/es
Priority to AU2011268876A priority patent/AU2011268876B2/en
Priority to PH1/2013/500050A priority patent/PH12013500050A1/en
Priority to CN201180031414.5A priority patent/CN102958940B/zh
Priority to ES11727457T priority patent/ES2531288T3/es
Priority to PL11727457T priority patent/PL2585480T3/pl
Priority to RS20150125A priority patent/RS53851B1/sr
Priority to EA201291362A priority patent/EA023005B1/ru
Priority to SG2012094660A priority patent/SG186439A1/en
Priority to EP11727457.1A priority patent/EP2585480B1/en
Priority to HK13105748.9A priority patent/HK1178908B/en
Priority to DK11727457.1T priority patent/DK2585480T5/en
Priority to JP2013515923A priority patent/JP5911481B2/ja
Priority to US13/806,072 priority patent/US9102759B2/en
Priority to SI201130372T priority patent/SI2585480T1/sl
Priority to KR1020137002118A priority patent/KR101861872B1/ko
Priority to HRP20150241TT priority patent/HRP20150241T1/hr
Priority to BR112012032708A priority patent/BR112012032708A2/pt
Publication of PL391627A1 publication Critical patent/PL391627A1/pl
Priority to IL223640A priority patent/IL223640A/en
Priority to ZA2013/00677A priority patent/ZA201300677B/en
Priority to CY20151100240T priority patent/CY1116099T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/80—Cytochromes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/07—Fusion polypeptide containing a localisation/targetting motif containing a mitochondrial localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL391627A 2010-06-25 2010-06-25 Przeciwnowotworowe białko fuzyjne PL391627A1 (pl)

Priority Applications (26)

Application Number Priority Date Filing Date Title
PL391627A PL391627A1 (pl) 2010-06-25 2010-06-25 Przeciwnowotworowe białko fuzyjne
KR1020137002118A KR101861872B1 (ko) 2010-06-25 2011-06-24 항암 융합 단백질
SG2012094660A SG186439A1 (en) 2010-06-25 2011-06-24 Anticancer fusion protein
PT11727457T PT2585480E (pt) 2010-06-25 2011-06-24 Proteína de fusão anticancro
CA2800841A CA2800841C (en) 2010-06-25 2011-06-24 Anticancer htrail/pre-apoptotic effector fusion proteins
MX2012015246A MX2012015246A (es) 2010-06-25 2011-06-24 Proteina de fusion anticancerigena.
AU2011268876A AU2011268876B2 (en) 2010-06-25 2011-06-24 Anticancer fusion protein
PH1/2013/500050A PH12013500050A1 (en) 2010-06-25 2011-06-24 Anticancer fusion protein
CN201180031414.5A CN102958940B (zh) 2010-06-25 2011-06-24 抗癌融合蛋白
ES11727457T ES2531288T3 (es) 2010-06-25 2011-06-24 Proteína de fusión anticancerígena
PL11727457T PL2585480T3 (pl) 2010-06-25 2011-06-24 Przeciwnowotworowe białko fuzyjne
RS20150125A RS53851B1 (sr) 2010-06-25 2011-06-24 Antikancerski fuzioni protein
EA201291362A EA023005B1 (ru) 2010-06-25 2011-06-24 Слитый белок против злокачественных новообразований
PCT/EP2011/060666 WO2011161260A1 (en) 2010-06-25 2011-06-24 Anticancer fusion protein
EP11727457.1A EP2585480B1 (en) 2010-06-25 2011-06-24 Anticancer fusion protein
SI201130372T SI2585480T1 (sl) 2010-06-25 2011-06-24 Fuzijski protein proti raku
DK11727457.1T DK2585480T5 (en) 2010-06-25 2011-06-24 Anticancer fusion protein
JP2013515923A JP5911481B2 (ja) 2010-06-25 2011-06-24 抗癌性融合タンパク質
US13/806,072 US9102759B2 (en) 2010-06-25 2011-06-24 Anticancer fusion protein comprising trail
HK13105748.9A HK1178908B (en) 2010-06-25 2011-06-24 Anticancer fusion protein
UAA201300877A UA111722C2 (uk) 2010-06-25 2011-06-24 Протираковий злитий протеїн
HRP20150241TT HRP20150241T1 (xx) 2010-06-25 2011-06-24 Antikancerogeni fuzijski protein
BR112012032708A BR112012032708A2 (pt) 2010-06-25 2011-06-24 proteína de fusão anticâncer.
IL223640A IL223640A (en) 2010-06-25 2012-12-13 Anticancer fusion protein
ZA2013/00677A ZA201300677B (en) 2010-06-25 2013-01-23 Anticancer fusion protein
CY20151100240T CY1116099T1 (el) 2010-06-25 2015-03-10 Πρωτεϊνη συντηξης κατα του καρκινου

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL391627A PL391627A1 (pl) 2010-06-25 2010-06-25 Przeciwnowotworowe białko fuzyjne

Publications (1)

Publication Number Publication Date
PL391627A1 true PL391627A1 (pl) 2012-01-02

Family

ID=44627460

Family Applications (2)

Application Number Title Priority Date Filing Date
PL391627A PL391627A1 (pl) 2010-06-25 2010-06-25 Przeciwnowotworowe białko fuzyjne
PL11727457T PL2585480T3 (pl) 2010-06-25 2011-06-24 Przeciwnowotworowe białko fuzyjne

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL11727457T PL2585480T3 (pl) 2010-06-25 2011-06-24 Przeciwnowotworowe białko fuzyjne

Country Status (24)

Country Link
US (1) US9102759B2 (pl)
EP (1) EP2585480B1 (pl)
JP (1) JP5911481B2 (pl)
KR (1) KR101861872B1 (pl)
CN (1) CN102958940B (pl)
AU (1) AU2011268876B2 (pl)
BR (1) BR112012032708A2 (pl)
CA (1) CA2800841C (pl)
CY (1) CY1116099T1 (pl)
DK (1) DK2585480T5 (pl)
EA (1) EA023005B1 (pl)
ES (1) ES2531288T3 (pl)
HR (1) HRP20150241T1 (pl)
IL (1) IL223640A (pl)
MX (1) MX2012015246A (pl)
PH (1) PH12013500050A1 (pl)
PL (2) PL391627A1 (pl)
PT (1) PT2585480E (pl)
RS (1) RS53851B1 (pl)
SG (1) SG186439A1 (pl)
SI (1) SI2585480T1 (pl)
UA (1) UA111722C2 (pl)
WO (1) WO2011161260A1 (pl)
ZA (1) ZA201300677B (pl)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL219845B1 (pl) * 2011-01-05 2015-07-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
ES2388020B1 (es) * 2011-03-10 2013-10-01 Universitat De Girona Proteínas recombinantes con efecto antitumoral.
PL394618A1 (pl) * 2011-04-19 2012-10-22 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
RU2631002C2 (ru) * 2012-12-05 2017-09-15 Тевакс Дженетикс Вэксин Ко., Лтд. Слитые белки для применения в качестве иммуногенных усиливающих агентов для индуцирования антигенспецифического т-клеточного ответа
WO2014141094A1 (en) 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Anticancer conjugate
CN103255160A (zh) * 2013-05-06 2013-08-21 徐霞 重组人可溶性肿瘤坏死因子相关的凋亡诱导配体的制备方法
CN103524627A (zh) * 2013-10-14 2014-01-22 成都华创生物技术有限公司 一种增强trail抗肿瘤活性的双靶点融合蛋白
JP2017513921A (ja) 2014-03-03 2017-06-01 アーチャルジー、スジャータ ジストロフィン異常症を治療するためのキメラジストロフィン−ｖｓｖ−ｇタンパク質
BR102014031185A8 (pt) * 2014-12-12 2021-05-04 Fund De Amparo A Pesquisa Do Estado De Sao Paulo Fapesp proteína recombinante indutora da apoptose; processo de obtenção da dita proteína e o seu uso no tratamento do câncer
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
WO2016127346A1 (zh) * 2015-02-11 2016-08-18 四川大学华西医院 一种肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途
CN105985445B (zh) * 2015-02-11 2020-02-04 四川大学华西医院 一种肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途
KR20170105107A (ko) * 2015-02-26 2017-09-18 더백스 제네틱스 백신 코포레이션, 엘티디. 항원-특이적인 t-세포 반응을 도출하는 데 사용하기 위한 면역원성 단백질 및 조합 아주반트를 포함하는 백신 조성물
WO2016138625A1 (zh) * 2015-03-02 2016-09-09 成都华创生物技术有限公司 TRAIL穿膜肽样突变体MuR6、制备方法及应用
EP3266796B1 (en) * 2015-03-02 2018-12-19 Chengdu Huachuang Biotechnology Co., Ltd Trail membrane-penetrating peptide-like mutant mur5, preparation method therefor, and application thereof
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EA201792573A1 (ru) 2015-05-21 2018-04-30 Харпун Терапьютикс, Инк. Триспецифические связанные белки и способы их применения
WO2017066963A1 (zh) * 2015-10-22 2017-04-27 成都华创生物技术有限公司 一种TRAIL双靶点突变蛋白MuR6S4TR、其制备方法及其应用
CN106459172B (zh) * 2015-10-22 2019-07-23 成都华创生物技术有限公司 一种TRAIL双靶点突变蛋白MuR5S4TR、其制备方法及其应用
WO2017123548A1 (en) * 2016-01-14 2017-07-20 Seattle Children's Hospital (dba Seattle Children's Research Institute) Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment
CN114028549A (zh) * 2016-02-19 2022-02-11 伊玛提克斯生物技术有限公司 用于nhl和其他癌症免疫治疗的新型肽和肽组合物
GB201602918D0 (en) * 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
JP7101621B2 (ja) 2016-05-20 2022-07-15 ハープーン セラピューティクス，インク． 単一ドメイン血清アルブミン結合タンパク質
US11939609B2 (en) 2017-07-24 2024-03-26 The Board Of Trustees Of The Leland Stanford Junior University Rewiring aberrant cancer signaling to a therapeutic effector response with a synthetic two-component system
HRP20241268T1 (hr) 2017-10-13 2024-12-06 Harpoon Therapeutics, Inc. Trispecifični proteini i postupci primjene
US11338028B2 (en) * 2017-12-13 2022-05-24 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting LEMD1 and uses thereof
WO2019147844A1 (en) * 2018-01-25 2019-08-01 University Of Washington Engineered cell death-inducing enzymes and methods of use
CN108324692B (zh) * 2018-04-26 2019-09-24 北京爱泰浦生物医药科技有限责任公司 Atap多肽和紫杉醇类药物共晶药及其制备方法和应用
KR20210020903A (ko) 2018-05-14 2021-02-24 하푼 테라퓨틱스, 인크. 면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티
EP3802619A1 (en) * 2018-06-08 2021-04-14 F. Hoffmann-La Roche AG Peptidic linker with reduced post-translational modification
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
US12428445B2 (en) 2018-11-08 2025-09-30 Adarsha Koirala Mini-nucleosome core proteins and use in nucleic acid delivery
MY205459A (en) 2018-12-06 2024-10-22 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
US12516128B2 (en) * 2019-05-14 2026-01-06 Harpoon Therapeutics, Inc. EpCAM binding proteins and methods of use
KR20220095193A (ko) * 2019-10-11 2022-07-06 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 조절 가능한 세포 국재화를 위한 재조합 폴리펩티드
IL297250A (en) 2020-04-13 2022-12-01 Summation Bio Inc Modified mini-nucleosome core proteins and use in nucleic acid delivery
US12416634B2 (en) * 2020-06-01 2025-09-16 Galderma Holding SA SNAP-25 reporter constructs and methods of using the same
CN113549143B (zh) 2021-07-21 2022-05-27 吉林大学 一种抗肿瘤多肽Bax-BH3、荧光高分子纳米胶束及其制备方法和应用
CN113717289A (zh) * 2021-07-23 2021-11-30 华东理工大学 一种sac-trail融合蛋白及其制备方法和应用
EP4396211A2 (en) * 2021-09-02 2024-07-10 UMC Utrecht Holding B.V. Pro-apoptotic construct and use thereof
WO2023076768A1 (en) * 2021-10-26 2023-05-04 Navicure Biopharmaceuticals Limited Combination therapies against cancer and infectious diseases
CN118103056A (zh) * 2021-11-05 2024-05-28 萨摩亚商柏沛生医股份有限公司 针对感染性动物疾病的免疫性融合蛋白
KR20240145409A (ko) * 2023-03-24 2024-10-07 카오티에스 주식회사 신규한 그랜자임 융합단백질 및 이의 용도

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60226816A (ja) 1984-11-16 1985-11-12 Asahi Chem Ind Co Ltd 抗腫瘍活性をもつヒト由来蛋白質
DE3841768A1 (de) 1988-12-12 1990-06-13 Basf Ag Neue tnf-peptide
US6284236B1 (en) * 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
AU708239B2 (en) * 1995-06-29 1999-07-29 Immunex Corporation Cytokine that induces apoptosis
US6962696B1 (en) * 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
US7297762B2 (en) 2000-04-24 2007-11-20 Yale University Modified avian pancreatic polypeptide miniature binding proteins
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
DE10247755B4 (de) 2002-10-14 2006-01-19 Pfizenmaier, Klaus, Prof. Dr. Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
CN1257187C (zh) * 2003-10-22 2006-05-24 上海恰尔生物技术有限公司 钙网蛋白－肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途
CN1256347C (zh) * 2003-12-10 2006-05-17 中国人民解放军第二军医大学 激肽原第五结构域－肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途
KR100685345B1 (ko) 2004-03-27 2007-02-22 학교법인조선대학교 세포사 유도 펩타이드
JP5186372B2 (ja) 2005-08-16 2013-04-17 ジェネンテック， インコーポレイテッド 細胞／組織においてｇａｌｎａｃ−ｔ１４発現を試験することによるａｐｏ２ｌ／ｔｒａｉｌに対するアポトーシス感受性
CN101168742A (zh) * 2007-03-08 2008-04-30 中山大学肿瘤防治中心 一种溶癌病毒及其制备方法
WO2009002947A2 (en) 2007-06-22 2008-12-31 Affymax, Inc. Compounds and peptides that bind the trail receptor
CN101157729B (zh) * 2007-10-23 2011-01-12 南京大学 一种肿瘤坏死因子相关凋亡配体变体及其应用
CL2009001191A1 (es) 2008-05-14 2010-07-02 Genentech Inc Uso del peptido apo2l/trail porque sirve para preparar un medicamento para tratar el cancer de pulmon y el linfoma de hodkin.
SG191698A1 (en) * 2008-06-30 2013-07-31 Univ Pennsylvania Fn14/trail fusion proteins
JP5700409B2 (ja) 2008-11-14 2015-04-15 国立大学法人京都大学 Ｈｓｐ９０を標的にした新規抗がんキメラペプチド

Also Published As

Publication number Publication date
JP2013532972A (ja) 2013-08-22
CN102958940B (zh) 2015-12-02
KR20130088137A (ko) 2013-08-07
EA201291362A1 (ru) 2013-06-28
DK2585480T3 (en) 2015-03-23
SI2585480T1 (sl) 2015-02-27
DK2585480T5 (en) 2015-06-08
PT2585480E (pt) 2015-03-02
HK1178908A1 (en) 2013-09-19
KR101861872B1 (ko) 2018-05-28
EP2585480A1 (en) 2013-05-01
CA2800841C (en) 2018-07-10
US9102759B2 (en) 2015-08-11
SG186439A1 (en) 2013-01-30
US20130164254A1 (en) 2013-06-27
CY1116099T1 (el) 2017-02-08
ZA201300677B (en) 2013-09-25
CA2800841A1 (en) 2011-12-29
JP5911481B2 (ja) 2016-04-27
WO2011161260A1 (en) 2011-12-29
HRP20150241T1 (xx) 2015-06-05
IL223640A (en) 2016-05-31
UA111722C2 (uk) 2016-06-10
EA023005B1 (ru) 2016-04-29
PL2585480T3 (pl) 2015-05-29
MX2012015246A (es) 2013-02-07
RS53851B1 (sr) 2015-08-31
EP2585480B1 (en) 2014-12-10
PH12013500050A1 (en) 2022-10-05
ES2531288T3 (es) 2015-03-12
CN102958940A (zh) 2013-03-06
AU2011268876A1 (en) 2013-01-10
AU2011268876B2 (en) 2014-01-30
BR112012032708A2 (pt) 2016-10-11

Similar Documents

Publication Publication Date Title
ZA201300677B (en) Anticancer fusion protein
ZA201404667B (en) Anticancer fusion protein
ZA201303449B (en) Anticancer fusion protein
GB201113558D0 (en) Kraftfahrzeugkarosserie mit strukturverstarkter vorderrahmenanbindung
SG10202100341XA (en) Npp1 fusion proteins
PT2661496T (pt) Proteína de fusão anticancerígena
ZA201405460B (en) Anticancer fusion protein
GB201116180D0 (en) Kraftfahrzeug mit warnsystem
IL226481A0 (en) Enzymes@Maochim
EP2698386B8 (en) Fusion protein
EP2657337A4 (en) FUSION PROTEIN
ZA201308597B (en) Anticancer fusion protein
GB201016494D0 (en) Polypeptide
ZA201207425B (en) Fusion protein
EP2521787A4 (en) IMPROVED PROTEIN EXPRESSION
GB201016346D0 (en) Connection means
PL393146A1 (pl) Przeciwnowotworowe białko fuzyjne
GB201007955D0 (en) Somatosatin fusion proteins
HK1189602A (en) Anticancer fusion protein
GB201010202D0 (en) Fusion polypeptides
GB201114701D0 (en) Fusion proteins
GB201107189D0 (en) Fusion proteins
ZA201301851B (en) Pharmaceutical combinations
GB201104152D0 (en) Fusion Polypeptide
AU2012902635A0 (en) Thirsty Pooch

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)